Skip to content
Beilai Bio logo — Advancing the future of healthcare with stem cell therapeuti...

Beilai Bio

Advancing the future of healthcare with stem cell therapeutics, converting medical waste into powerful solutions for high unmet medical needs.

Founded 2015 Series B Total: $300.00M Biotechnology

General Information

Company Name Beilai Bio
Founded Year 2015
Industries Biotechnology
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Beilai Bio. To contact Beilai Bio, visit baylxinc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Beilai Bio compare?

A PDF of Beilai Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Beilai Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Beilai Bio

Beilai Bio is a clinical-stage biopharmaceutical company founded in 2015 that is at the forefront of advancing the future of healthcare with its focus on stem cell therapeutics. The company's slogan "Advancing the future of healthcare with stem cell therapeutics, converting medical waste into powerful solutions for high unmet medical needs" encapsulates its mission to address significant unmet medical needs. Beilai Bio concentrates on developing stem cell therapies for a wide range of diseases, leveraging its advanced technology platforms to produce clinical-grade "off-the-shelf" Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC) derived from an unlimited supply of cord tissues, typically considered as medical waste.

The company recently secured a CNY300.00M Series B investment on 15 April 2022, demonstrating significant confidence from investors in its innovative approach. Notable investors in this round include DT Capital Partners, SDIC Ventures, Huajin Capital, and Nanjing Jiangbei New Area Industrial Investment Group. Beilai Bio operates in the biotechnology industry, positioning itself in a rapidly evolving and impactful sector.

Overall, Beilai Bio's innovative technology, focus on addressing unmet medical needs, and recent substantial investment signify its potential to make a lasting impact in the healthcare and biopharmaceutical landscape.

Business keywords: biopharmaceuticals, stem cell therapy, clinical-stage, medical waste utilization, unmet medical needs, advanced technology platforms, hUC-MSC, cord tissue, clinical-grade production, biopharmaceutical development, disease treatment, clinical trials, regenerative medicine, cord tissue utilization

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series B CNY300.00M 4
DT Capital Partners, SDIC Ventures +2
15 Apr 2022

Beilai Bio Alternatives & Competitors

View All Alternatives
Beilai Bio vs

Pioneering new hope for incurable diseases through groundbreaking stem cell therapies and unwavering...

Private Equity
3 employees
Biotechnology
Beilai Bio vs

‘Off-the-Shelf’ Curative Cell Therapies

Pre-Seed
3 employees
Biotechnology, Health and Wellness
Beilai Bio vs
Athersys
Athersys United States

Committed to developing therapies to extend and enhance the quality of life.

Post-IPO Equity
37 employees
Biopharma, Biotechnology

FAQ About Beilai Bio

Advancing the future of healthcare with stem cell therapeutics, converting medical waste into powerful solutions for high unmet medical needs.
Beilai Bio was founded in 2015.
Beilai Bio operates in Biotechnology. Its work centres on biopharmaceuticals, stem cell therapy, clinical-stage and medical waste utilization.
Beilai Bio has completed 1 funding round, raising a total of $300.00M. The latest funding stage is Series B.
Top alternatives and competitors to Beilai Bio include Medipost Co Ltd, Cell BioEngines, Inc, Athersys, Stemedica Cell Technologies, Inc, Targazyme. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Beilai Bio and Medipost Co Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Beilai Bio, https://bouncewatch.com/company/beilai-bio, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout